Substance for Treating and/or Preventing Allergic Diseases, and Design Method and Preparation Method thereof

Abstract

The present invention discloses a substance for treating and/or preventing allergic diseases and a design method and preparation method thereof. The stable structure corresponding to the substance related to the allergic disease is used as the substance for treating and/or preventing the allergic disease. The essence of disease is the imbalance of biological structure system. The imbalance of the structure of the substance in the biological structure system will cause diseases related to said substance. The present disclosure relates to the treatment and/or prevention of the allergic disease by recognizing the stable structure corresponding to the substance by the body, adjusting the expression of its gene expression or genes by the self-adaptation, self-organization and other functions of body's structural system, and restoring the balance of the structure of the substance in the biological structure system.

Claims

1.-181. (canceled)

182. A method for designing substance for treating and/or preventing allergic diseases, characterized in that: the stable structure corresponding to the substance related to the allergic disease is used as the substance for treating and/or preventing said allergic disease; and the stable structure corresponding to the substance is characterized by the structure of said substance that exists in a solid state at a temperature of 500° C. or higher.

183. The method according to claim 182, characterized in that said stable structure corresponding to the substance related to the allergic disease is selected from one or more of the following: (1) the stable structure corresponding to the substance that causes allergic disease in the organism; (2) the stable structure corresponding to the substance of the organism itself and related to allergic disease; (3) the stable structure corresponding to the substance that inhibits the structure that causes allergic disease; (4) the stable structure corresponding to the substance containing a substance of any one of (1) to (3) above.

184. The method according to claim 182, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

185. The method according to claim 183, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

186. A substance for treating and/or preventing allergic diseases designed by a method characterized in that: the stable structure corresponding to the substance related to the allergic disease is used as the substance for treating and/or preventing said allergic disease; and the stable structure corresponding to the substance is characterized by the structure of said substance that exists in a solid state at a temperature of 500° C. or higher.

187. The substance according to claim 186, characterized in that said stable structure corresponding to the substance related to the allergic disease is selected from one or more of the following: (1) the stable structure corresponding to the substance that causes allergic disease in the organism; (2) the stable structure corresponding to the substance of the organism itself and related to allergic disease; (3) the stable structure corresponding to the substance that inhibits the structure that causes allergic disease; (4) the stable structure corresponding to the substance containing a substance of any one of (1) to (3) above.

188. The substance according to claim 186, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

189. The substance according to claim 187, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

190. A method of preparing the substance of claim 186, characterized in that the stable structure corresponding to the substance is prepared by a high-temperature carbonization method.

191. The method according to claim 190, characterized in that said stable structure corresponding to the substance related to the allergic disease is selected from one or more of the following: (1) the stable structure corresponding to the substance that causes allergic disease in the organism; (2) the stable structure corresponding to the substance of the organism itself and related to allergic disease; (3) the stable structure corresponding to the substance that inhibits the structure that causes allergic disease; (4) the stable structure corresponding to the substance containing a substance of any one of (1) to (3) above.

192. The method according to claim 190, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

193. The method according to claim 191, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

194. A method of treating and/or preventing an allergic disease in a subject in need thereof, comprising administering the substance of claim 186 to the subject.

195. The method according to claim 194, wherein said allergic disease is selected from food allergic disease, peanut allergy, egg allergy, milk allergy, soybean allergy, nuts allergy, fish allergy, crustacean allergy, wheat allergy, shrimp allergy, fruit allergy, vagetable allergy, plant seed allergy, food additive allergy, meat allergy, alcohol allergy, room/house dust mite allergy, dust allergy, fungal allergy, pollen allergy, ragweed pollen allergy, birch pollen allergy, Artemisia pollen allergy, cedar pollen allergy, maple pollen allergy, humulus pollen allergy, willow catkins allergy, sycamore pollen allergy, ginkgo pollen allergy, cat hair allergy, dog hair allergy, cockroach allergy, drug allergy, antibiotics allergy, anesthetic allergy, sulfonamides allergy, chemical/chemical raw materials allergy, Thiuram mix allergy, formaldehyde allergy, spice mixture allergy, fragrance mix allergy, Balsam of Peru allergy, lanolin alcohol allergy, and chlorides allergy.

Description

DETAILED DESCRIPTION

[0843] The present invention discloses substances for treating and/or preventing allergic diseases, the design method and the preparation method thereof. Those skilled in the art can learn from the content of this article, use different materials, improve the process or adopt other similar processes for preparation, all of which are considered to be included in the present invention. In particular, it should be pointed out that all such substitutions and modifications will be apparent to those skilled in the art and are intended to be included herein. While the methods and products of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the methods described herein, as well as appropriate variations and combinations, may be made to implement and use the techniques of the present invention without departing from the spirit and scope of the invention.

[0844] In order to further understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the examples of the present invention, and it is obvious that the described examples are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.

[0845] The Specific Embodiments are as Follows:

EXAMPLE 1

Substance for Treating and/or Preventing Shrimp Allergy, and Design Method and Preparation Method Thereof

[0846] Since shrimps contain substances causing shrimp allergy and are easily available, it is preferable to use the stable structure corresponding to shrimp as the substance for treating and/or preventing shrimp allergy. If other organs or tissues also contain the substance related to the shrimp allergy disease, it is also preferable to use the stable structure corresponding to the organ or tissue containing the substance related to the shrimp allergy disease as the substance for treating and/or preventing shrimp allergy, so that the complicated problems can be simplified, and the substance for treating and/or preventing shrimp allergy can be designed and prepared without knowing the specific allergen structure and pathogenic mechanism.

[0847] The shrimp is carbonized at high temperature to obtain the substance for treating and/or preventing shrimp allergy.

[0848] Using the same method, the present invention prepared a series of substances for treating and/or preventing allergic diseases caused by different food allergens.

EXAMPLE 2

Substance for Treating and/or Preventing Artemisia Pollen Allergy, and Design Method nd Preparation Method Thereof

[0849] Since Artemisia pollen contains substances causing Artemisia pollen allergy and is easily available, it is preferable to use the stable structure corresponding to Artemisia pollen as the substance for treating and/or preventing Artemisia pollen allergy. If other organs or tissues also contain the substance related to the Artemisia pollen allergy disease, it is also preferable to use the stable structure corresponding to the organ or tissue containing the substance related to the Artemisia pollen allergy disease as the substance for treating and/or preventing Artemisia pollen allergy, so that the complicated problems can be simplified, and the substance for treating and/or preventing Artemisia pollen allergy can be designed and prepared without knowing the specific allergen structure and pathogenic mechanism.

[0850] The Artemisia pollen is carbonized at high temperature to obtain the substance for treating and/or preventing Artemisia pollen allergy.

[0851] Using the same method, the present invention prepared a series of substances for treating and/or preventing biological allergic diseases caused by different pollen allergens.

EXAMPLE 3

Clinical Application Test of the Substances Prepared in Example 1 and Example 2 and Various Substances for Treating Allergic Diseases Prepared in the Same Manner in the Treatment of Allergic Diseases

[0852] The present invention uses the substances prepared in the above Example 1 and Example 2 for efficacy verification, and the details are as follows: [0853] 1. Clinical data: Clinical validation was performed from May 2018 to May 2019. The specific process comprises the steps of hospitalizing the patient, self-describing symptoms by the pateint, carrying out allergy tests (skin test, blood test and the like) to confirm the allergen, carrying out targeted treatment for different allergens once. If there are too many allergens, a second targeted treatment will be carried out. After treatment, testing whether the patient was desensitized to the allergen by direct contact or consumption of the allergen, carrying out the same allergy tests, and further verifying the desensitization effect by comparing testing indexes. A total of 108 patients with allergies in the outpatient and inpatient departments were collected and randomly divided into treatment group and control group, with 54 patients in each group. There was no significant difference in clinical data between the two groups. Statistical analysis of age, disease course, gender, allergens, complications, etc. between the two groups showed that the differences were not significant (P>0.05), and they were comparable. [0854] 2. Diagnostic criteria: Refer to the “Guidelines for the European Society of Allergy and Clinical Immunology (2007)” and the “WAO Guidelines for the Diagnosis of Severe Allergic Reactions” for the diagnosis of allergies. [0855] 3. Treatment method: Patients in the treatment group were orally administered the substance for treating allergic diseases of the present invention once a day, 3 g/time, for 3 days continuously; patients in the control group were treated with conventional western medicine or desensitization therapy according to the doctor's instructions, including injection desensitization, sublingual desensitization, desensitization patch, antihistamine drugs, allergic reaction mediator blockers, corticosteroids, calcium agents, immunosuppressants, etc. [0856] 4. Criteria for judging the treatment effect: The treatment effect of the disease is evaluated according to the symptoms, and the total effective rate=cure rate+marked improvement rate+effective rate, wherein “cure” means that the clinical symptoms of allergy of the patient completely disappeared after treatment, no allergic reaction occurs after the patient contacts with the allergen again, and no recurrence occurs within 1 year of follow-up; “marked improvement” means that the clinical symptoms of the patient are significantly improved after treatment, no allergic reaction occurs after the patient contacts with the allergen again, and recurrence occurs within 1 year of follow-up; “effective” means that the clinical symptoms of the patient are relieved to some extent after treatment, and compared with before treatment, allergic symptoms are alleviated when exposed to allergens again; “ineffective” means that the above clinical symptoms and manifestations of the patient have not changed significantly or worsened after treatment. [0857] 5. Efficacy results: As shown in Table 1, the overall treatment effect of the control group was “marked improvement” in 2 cases, “effective” in 17 cases, and “ineffective” in 35 cases. More than 95% of patients still have allergic symptoms after being exposed to allergens again. In all 3 patients treated with desensitization therapy, the treatment was terminated early because of obvious intolerance. In the control group, there were 27 cases of adverse drug reactions and 14 cases of drug tolerance. The drugs needed to be changed or increased doses according to doctor's orders.

[0858] In the treatment group, 52 patients were cured, with a total effective rate of 96.30%, and the patients did not develop allergic symptoms after repeated exposure to allergens. At the same time, there were no side effects and drug dependence in the treatment group during the observation period.

TABLE-US-00001 TABLE 1 Comparison of the treatment effect of allergic patients (cases) Total Number Marked effective Group of cases Cure improvement Effective Ineffective rate (%) Treatment 54 52 0 0 2 96.30 group Control 54 0 2 17 35 35.19 group